BIOLINERX     Print Page  Close Window

SEC filings
BIOLINERX LTD. filed this Form F-1 on 10/02/2012
Entire Document

We expect our revenues for the next several years to be derived primarily from payments under our current agreement with Ikaria, as well as additional collaborations that we may enter into in the future, including with regard to BL-1020, BL-5010, BL-7040, BL-8040, BL-1021 or other therapeutic candidates. Furthermore, we may receive future royalties on product sales, if any, under our agreement with Ikaria, as well as under any future agreement relating to BL-1020, BL-5010, BL-7040, BL-8040, BL-1021 or other compounds.
            Our remaining therapeutic candidates are currently in development and, therefore, we do not expect to generate any revenues from these products for at least the next several years, if at all.
Research and Development
Our research and development expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory supplies and costs for facilities and equipment. We primarily use external service providers to manufacture our product candidates for clinical trials and for the majority of our preclinical and clinical development work. We charge all research and development expenses to operations as they are incurred. We expect our research and development expense to remain our primary expense in the near future as we continue to develop our therapeutic candidates.
The following table identifies our current major research and development projects:
Expected or Recent Near Term Milestone
Phase 2/3 CLARITY trial
CLARITY study results- second half of 2013
CE registration pivotal trial
PRESERVATION 1 study results – first half of 2014
Completed phase 1/2
Completion of unique applicator prototype by end of 2012; commencement of pivotal CE Mark registration trial in first half of 2013
Phase 2a trial
Study results - end of 2012/early 2013
Completed phase 1/2
Phase 2 expected to commence during the first half of 2013
Completed phase 1a
Phase 1b multiple ascending dose study